Global Recombinant Human Coagulation VIIa Market Growth 2023-2029

Global Recombinant Human Coagulation VIIa Market Growth 2023-2029

Recombinant activated factor VII (rFVIIa) binds to exposed tissue factor at the place of tissue and vascular injury. Thrombin generated by this process activates platelets and the coagulation cascade.

LPI (LP Information)' newest research report, the “Recombinant Human Coagulation VIIa Industry Forecast” looks at past sales and reviews total world Recombinant Human Coagulation VIIa sales in 2022, providing a comprehensive analysis by region and market sector of projected Recombinant Human Coagulation VIIa sales for 2023 through 2029. With Recombinant Human Coagulation VIIa sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Human Coagulation VIIa industry.

This Insight Report provides a comprehensive analysis of the global Recombinant Human Coagulation VIIa landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Human Coagulation VIIa portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Recombinant Human Coagulation VIIa market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Human Coagulation VIIa and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Human Coagulation VIIa.

The global Recombinant Human Coagulation VIIa market size is projected to grow from US$ 1109.1 million in 2022 to US$ 1443.7 million in 2029; it is expected to grow at a CAGR of 1443.7 from 2023 to 2029.

The top three manufacturers of recombinant human coagulation VIIa in the world include Novo Nordisk, LFB SA HEMA Biologics, and GENERIUM, with a total market share of more than 99%. The largest manufacturer is Novo Nordisk, with a market share of more than 95%. North America is the global most important consumer market for recombinant human coagulation VIIa, with a market share of about 45%. In terms of type, the market share of prefilled syringe is over 78%. In the field of application, the market share of congenital hemophilia is about 65%.

This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Human Coagulation VIIa market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Prefilled Syringe
Vial

Segmentation by application
Congenital Hemophilia
Acquired Hemophilia
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
LFB SA HEMA Biologics
AryoGen Pharmed
GENERIUM

Key Questions Addressed in this Report

What is the 10-year outlook for the global Recombinant Human Coagulation VIIa market?

What factors are driving Recombinant Human Coagulation VIIa market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Recombinant Human Coagulation VIIa market opportunities vary by end market size?

How does Recombinant Human Coagulation VIIa break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.